Fakhar Siddiqui, MD, MBA

Merck & Co., Inc.

Disclosure(s): Merck & Co., Inc.: employee, Stocks/Bonds

Poster(s):

• 379 - A budget impact analysis of bezlotoxumab for the management of recurrent Clostridioides difficile infection in the United States
  Thursday, October 20, 2022

  12:15 PM – 1:30 PM US ET

• 1670 - Activity of Ceftolozane/Tazobactam and Comparators Against Clinical MDR and DTR Pseudomonas aeruginosa isolates – SMART United States 2018-2020
  Saturday, October 22, 2022

  12:15 PM – 1:30 PM US ET

• 1671 - Activity of Imipenem/Relebactam and Comparators Against Gram-Negative MDR and DTR Pathogens from Patients with Respiratory and Bloodstream Infections – SMART United States 2018-2020
  Saturday, October 22, 2022

  12:15 PM – 1:30 PM US ET

• 1674 - Trends in Antimicrobial Susceptibility to Ceftolozane/Tazobactam and Comparators of Pseudomonas aeruginosa from Patients with Respiratory Tract Infections in Five Latin American Countries – SMART 2017-2020
  Saturday, October 22, 2022

  12:15 PM – 1:30 PM US ET

• 1718 - In Vitro Activity of Imipenem/Relebactam against Class C β-lactamase-Positive Enterobacterales in the Asia/Pacific Region: SMART 2018-2020
  Saturday, October 22, 2022

  12:15 PM – 1:30 PM US ET